Monday, 02 October 2023
COMMERCIAL PRODUCTS | THERAPEUTIC CATEGORY | STATUS |
---|---|---|
Clidinium Bromide | Anti-cholinergic | Commercial |
Atropine Sulphate | Anti-cholinergic | Commercial |
Homatropine Methylbromide | Anti-cholinergic | Commercial |
Homatropine Hydrobromide | Anti-cholinergic | Commercial |
Buprenorphine Base | Pain Management/De addiction | Commercial |
Buprenorphine HCl | Pain Management/De addiction | Commercial |
Naloxone HCl | Pain Management/De addiction | Commercial |
Oxybutynin Chloride/ Hydrochloride | Anti-cholinergic | Commercial,CEP |
Glycopyrrolate/Glycopyronium Bromide | Anti-cholinergic | Commercial |
Glycopyrrolate/Glycopyronium Bromide - Micronised (D90 < 6 micron, D99 < 10 micron) | Anti-cholinergic Inhalation | Commercial |
Isopropamide Iodide | Anti-cholinergic | Commercial |
Pramoxine HCl | Topical Anaesthetic | Commercial |
Naltrexone HCl | Pain Management/De addiction | Under Development |
Etizolam | Anxiolytic | Under Development |
Baclofen | Muscle Spasticity | Under Development |
Prazepam | Anxiolytic | Under Development |
Loprazolam | Anxiolytic | Under Development |
Ipratropium Bromide | COPD, Asthma | Commercial |
Clotiazepam | Anxiolytic | Under Development |
Zolpidem Tartrate | Anxiolytic | Commercial |
Midazolam | Hypnotics | Commercial |